Seretide Evohaler (fluticasone + salmeterol): Uses, Dosage & Side Effects

What it's for (Indications)

Fluticasone propionate and salmeterol xinafoate inhalation powder is indicated for the long-term, twice-daily maintenance treatment of asthma in patients 12 years of age and older.
It is also indicated for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and/or emphysema.
This medication is specifically designed for the regular management of symptoms and prevention of asthma exacerbations, as well as the improvement of lung function in COPD patients.
It is crucial to emphasize that this combination therapy is not indicated for the relief of acute bronchospasm; patients should be advised to have a short-acting beta-2 agonist (SABA) available for such acute episodes.
The synergistic action of an inhaled corticosteroid (ICS) and a long-acting beta-2 agonist (LABA) effectively controls airway inflammation and provides sustained bronchodilation, thereby reducing the frequency and severity of respiratory symptoms and improving overall lung function in appropriately selected patients.
Its primary role is in disease control and prevention of future events, not acute rescue.

Dosage Information

Type	Guideline
Standard	The recommended dosage regimen for fluticasone propionate and salmeterol xinafoate inhalation powder is two inhalations, twice daily, approximately 12 hours apart, for both asthma and COPD management. Available strengths typically include different ratios of fluticasone to salmeterol, such as 100/50 mcg, 250/50 mcg, and 500/50 mcg per inhalation for devices like the Diskus. The specific strength prescribed is determined by the patient's individual response, disease severity, and prior corticosteroid therapy. Patients must receive thorough instruction on the correct inhalation technique to ensure optimal drug delivery to the lungs. To minimize the risk of oral candidiasis (thrush) and potential systemic corticosteroid absorption, patients should be advised to rinse their mouth with water and spit it out immediately after each use. Adherence to the prescribed twice-daily schedule is paramount for maintaining therapeutic effects and achieving effective symptom control. This medication should never be used more frequently than recommended, and the prescribed dose should not be exceeded.

Type

Guideline

Standard

The recommended dosage regimen for fluticasone propionate and salmeterol xinafoate inhalation powder is two inhalations, twice daily, approximately 12 hours apart, for both asthma and COPD management. Available strengths typically include different ratios of fluticasone to salmeterol, such as 100/50 mcg, 250/50 mcg, and 500/50 mcg per inhalation for devices like the Diskus. The specific strength prescribed is determined by the patient's individual response, disease severity, and prior corticosteroid therapy. Patients must receive thorough instruction on the correct inhalation technique to ensure optimal drug delivery to the lungs. To minimize the risk of oral candidiasis (thrush) and potential systemic corticosteroid absorption, patients should be advised to rinse their mouth with water and spit it out immediately after each use. Adherence to the prescribed twice-daily schedule is paramount for maintaining therapeutic effects and achieving effective symptom control. This medication should never be used more frequently than recommended, and the prescribed dose should not be exceeded.

Safety & Warnings

Common Side Effects

Commonly reported adverse effects associated with fluticasone propionate and salmeterol xinafoate include upper respiratory tract infection, pharyngitis, oral candidiasis (thrush), dysphonia (hoarseness), headache, and tremor.
Palpitations, tachycardia, and muscle cramps may also occur due to the beta-agonist component.
More serious, though less common, adverse effects can include paradoxical bronchospasm, which is a potentially life-threatening condition requiring immediate discontinuation of the drug and institution of alternative therapy.
Systemic corticosteroid effects, such as adrenal suppression, decreased bone mineral density (osteoporosis), glaucoma, cataracts, and growth retardation in children, may manifest with long-term use, particularly at higher doses.
Patients with COPD may have an increased risk of developing pneumonia.
Hypersensitivity reactions, including angioedema, urticaria, bronchospasm, and rash, although rare, warrant immediate medical attention.
Regular monitoring for these adverse events, especially during long-term therapy, is an essential component of patient care.

Serious Warnings

Black Box Warning: **WARNING: ASTHMA-RELATED DEATH** Long-acting beta-2 adrenergic agonists (LABA), such as salmeterol, the bronchodilator component of fluticasone propionate and salmeterol xinafoate, increase the risk of asthma-related death. Data from a large, randomized, placebo-controlled clinical trial demonstrated that LABA monotherapy significantly increases the risk of asthma-related death. This finding is considered a class effect of LABA, including salmeterol. Therefore, fluticasone propionate and salmeterol xinafoate is contraindicated for patients with asthma without concomitant use of an inhaled corticosteroid. However, the combination of an inhaled corticosteroid and a LABA has been shown to mitigate this risk. This product should only be used in patients with asthma not adequately controlled on an inhaled corticosteroid alone or whose disease severity clearly warrants initiation of both an inhaled corticosteroid and a LABA. It is imperative that this combination product is not indicated for the primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required. Patients should be thoroughly educated on the risks and appropriate use of this medication.
Fluticasone propionate and salmeterol xinafoate is strictly a long-term maintenance treatment and must not be used for the relief of acute symptoms of asthma or COPD; patients require a rapid-acting inhaled bronchodilator for acute episodes.
It should not be initiated in patients experiencing rapidly deteriorating asthma or COPD, or for the primary treatment of status asthmaticus.
Abrupt discontinuation of corticosteroids can precipitate adrenal insufficiency, thus patients previously on systemic corticosteroids should be carefully monitored during transfer to inhaled therapy.
The LABA component, salmeterol, carries a warning regarding an increased risk of asthma-related death when used as monotherapy; however, this risk is generally considered to be mitigated when used in combination with an inhaled corticosteroid.
Patients should be cautioned against using additional LABAs while on this therapy.
This medication should be used with extreme caution in patients with cardiovascular disorders (e.
g.
, coronary insufficiency, cardiac arrhythmias, hypertension), convulsive disorders, thyrotoxicosis, or diabetes mellitus, as beta-adrenergic agonists can exacerbate these conditions.
Care is also required for patients with active or quiescent tuberculosis, untreated fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex due to the immunosuppressive effects of the corticosteroid.
Close monitoring for signs of glaucoma or cataracts is also recommended.

How it Works (Mechanism of Action)

Fluticasone propionate and salmeterol xinafoate represents a fixed-dose combination combining two distinct pharmacological agents to provide comprehensive therapeutic benefits for respiratory conditions. Fluticasone propionate is a highly potent synthetic trifluorinated corticosteroid with significant anti-inflammatory activity. It exerts its effects by binding to glucocorticoid receptors in the cytoplasm, translocating to the cell nucleus, and subsequently modulating gene expression. This process leads to the downregulation of genes encoding inflammatory mediators (e.g., cytokines, chemokines, eicosanoids) and the upregulation of genes encoding anti-inflammatory proteins, thereby reducing airway hyperresponsiveness and inflammation. Salmeterol xinafoate is a long-acting beta-2 adrenergic agonist (LABA). It acts by selectively stimulating beta-2 receptors primarily located in the bronchial smooth muscle, leading to dose-dependent relaxation and sustained bronchodilation. Its unique lipophilic side chain allows it to anchor in the cell membrane, providing a prolonged bronchodilatory effect for approximately 12 hours. The synergistic action of these two components effectively addresses both the underlying inflammatory processes and the reversible airway obstruction, which are hallmarks of asthma and COPD.